Zydus in-licenses critical drug for CKD patients from Pharmacosmos

Zydus Lifesciences has acquired rights to market MonoFerric (iron isomaltoside) injections in India and Nepal from Denmark-based Pharmacosmos A/S. MonoFerric 1000 solution for injection/infusion is a rapid, single-dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile, according to a statement from Zydus.

The statement also said that MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. It is available in over 30 countries including the US and Europe, and over 28 million doses have been administered since the launch.